10-Q/A: Mangoceuticals Reports Q2 2025 Loss Amid IP Acquisitions

Mangoceuticals, Inc. filed an amended quarterly report for Q2 2025, revealing increased net losses and significant stock-based compensation, alongside strategic intellectual property acquisitions and ongoing financing efforts.

Summary

• Net loss for the three months ended June 30, 2025, increased to $5,415,820 from $2,391,319 in the prior year, a 126% increase.
• Net loss for the six months ended June 30, 2025, increased to $10,255,309 from $4,758,936 in the prior year, a 115% increase.
• Revenues for the three months ended June 30, 2025, slightly increased to $168,109 from $163,163 in the prior year.
• Revenues for the six months ended June 30, 2025, decreased to $277,415 from $377,258 in the prior year, primarily due to telemedicine platform transition issues.
• Stock-based compensation significantly increased to $3,120,445 for the three months and $4,165,924 for the six months ended June 30, 2025, reflecting greater use of equity incentives.
• General and administrative expenses rose to $1,245,360 for the three months and $2,787,804 for the six months ended June 30, 2025, driven by legal, consulting, and acquisition-related costs.
• The company settled a lawsuit with Eli Lilly and Company for $20,000 in cash and agreed to cease marketing Tirzepatide-based TRIM products.
• Working capital deficit stood at $1.48 million as of June 30, 2025, and the company requires additional funding to continue operations for the next 12 months.
• Intangible assets, primarily acquired patents and license agreements, increased significantly to $20,694,893 as of June 30, 2025, from $15,232,617 at December 31, 2024.
• The company completed several capital raises through the issuance of Series B Convertible Preferred Stock, common stock, and warrants, generating substantial proceeds.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including increasing net losses, declining year-to-date revenue, and a stated need for ongoing capital raises to maintain operations. While there are strategic IP acquisitions and product diversification efforts, these are currently overshadowed by operational losses and going concern doubts. The high reliance on equity-based compensation and dilutive financing further contributes to a negative outlook for existing shareholders.

Positives

• Cash and cash equivalents increased to $101,019 as of June 30, 2025, from $58,653 at December 31, 2024, primarily due to financing activities.
• Successful settlement of the Eli Lilly lawsuit for $20,000 cash and agreement to cease marketing specific products, avoiding potentially larger liabilities.
• Acquisition of new intellectual property, including patents for respiratory illness prevention technology and mushroom-derived compositions, expanding the company's product pipeline.
• Entry into a Master Distribution Agreement with PrevenTech Solutions, LLC, granting exclusive worldwide licensing and distribution rights for respiratory illness prevention technology, with a 10% royalty on net sales.
• Strategic amendment of Series B Convertible Preferred Stock terms, reducing conversion and floor prices to $1.50 per share, potentially facilitating conversions and simplifying capital structure.

Negatives

• Significant increase in net loss for both the three-month ($5.42 million) and six-month ($10.26 million) periods ended June 30, 2025, compared to the prior year.
• Decrease in revenues for the six months ended June 30, 2025, attributed to issues with telemedicine platform transition and migration.
• Substantial increase in general and administrative expenses, salaries and benefits, investor relations, and stock-based compensation, contributing to higher operating losses.
• The company has a limited operating history, has produced only a limited amount of products, and has generated only limited revenues to date.
• The company has a working capital deficit of $1.48 million as of June 30, 2025, and requires additional funding to sustain operations for the next 12 months.
• The company's independent registered public accounting firm included an explanatory paragraph in its report on the condensed consolidated financial statements as of December 31, 2024, regarding going concern doubt.
• Rescission of the Master Distribution Agreement with Navy Wharf, Ltd. for Diabetinol, resulting in the cancellation of 1,000,000 shares previously issued, indicating a failed strategic initiative.

Risks

• Ability to obtain additional funding, the terms of such funding, and dilution caused thereby.
• Limited operating history, limited product production, and limited revenues to date.
• Ability to execute growth strategy, scale operations, and attract members and customers.
• Risks associated with products not being FDA approved and not having the benefit of FDA clinical trial protocols.
• Risk that the FDA may determine compounding of products does not fall within the exemption from the FFDCA Act.
• Significant reliance on related party transactions and risks associated with such relationships and agreements.
• Effect of data security breaches, malicious code, and/or hackers.
• Competition and ability to create a well-known brand name.
• Changes in consumer tastes and preferences.
• Material changes and/or terminations of relationships with key parties.
• Significant product returns, product liability, recalls, and litigation associated with tainted products or health issues.
• Ability to innovate, expand offerings, and compete against competitors with greater resources.
• Ability to prevent credit card and payment fraud.
• Risks associated with inflation, changes in interest rates, tariffs, trade wars, economic downturns, geopolitical events, and large-scale crises.
• Risk of unauthorized access to confidential information.
• Ability to protect intellectual property and trade secrets, and claims of infringement.
• Ability to adequately support future growth.
• Compliance with government regulations, changing regulations, laws, and penalties for non-compliance.
• Reliance on current management and terms of employment agreements.
• Outcome of lawsuits, litigation, regulatory matters, or claims.
• Certain terms and provisions of governing documents which may prevent a change of control, provide indemnification, limit liability, and allow for blank check preferred stock issuance.
• Volatile nature of common stock trading price and dilution from future sales of securities.

Future Outlook

The company anticipates needing additional funding to continue operations at current levels and to pay public company costs for the next 12 months, with potential future funding for expansion or acquisitions. It plans to pursue an aggressive growth strategy through marketing, product expansion, technology enhancements, and strategic acquisitions in the health and wellness space. A strategic review process is underway to evaluate potential mergers, acquisitions, divestitures, and other transactions to maximize shareholder value, with no set timeline for completion.

Management Comments

• "We currently anticipate the need for additional funding in order to continue our operations at their current levels and to pay the costs associated with being a public company for the next 12 months."
• "Our plan for the next 12 months is to continue using the same marketing and management strategies and continue providing a quality product with excellent customer service while also seeking to expand our operations organically or through acquisitions as funding and opportunities arise."
• "As our business continues to grow, customer feedback will be integral in making small adjustments to improve products and our overall customer experience."
• "We are headquartered in Dallas, Texas and intend to grow our business both organically and through identifying acquisition targets over the next 12 months in the technology, health and wellness space, funding permitting."
• "Specifically, we plan to continue to make additional and ongoing technology enhancements to our platform, further develop, market and advertise additional mens health and wellness related products on our telemedicine platform, and identify strategic acquisitions that complement our vision."
• "There is no assurance that the strategic review process will result in the approval or completion of any specific transaction or outcome."

Industry Context

Mangoceuticals operates in the growing men's wellness telemedicine sector, focusing on ED, hair loss, testosterone replacement, and weight management. The company faces intense competition and regulatory scrutiny, particularly regarding its compounded products which are not FDA-approved. Its strategy of acquiring intellectual property and entering distribution agreements for new product lines like Dermytol and respiratory illness prevention technology indicates an attempt to diversify and capture broader health and wellness market segments. The reliance on related-party pharmacies and ongoing capital raises highlights the challenges faced by smaller players in a competitive, capital-intensive industry.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Eli Lilly and Company filed a complaint against the company for false and misleading advertising and promotion related to the TRIM product, seeking declaratory judgment, injunction, corrective advertising, profits, and damages. This lawsuit was settled on June 23, 2025, for $20,000 cash and an agreement to cease marketing Tirzepatide-based TRIM products.
• Boustead Securities, LLC initiated an arbitration action with FINRA claiming over $1,000,000 in cash and warrants for financial advisory services for transactions the company believes Boustead is not entitled to. The company intends to vigorously defend against this claim.

Related Party Transactions

• Epiq Scripts, LLC (52% owned by CEO Jacob Cohen) serves as the related party compounding pharmacy for the company's Compounded Products and Prime.
• On January 30, 2025, the company assigned its rights under Master Services Agreement and Consulting Agreement with Epiq Scripts to Mango & Peaches, with mutual indemnification.
• Ronin Equity Partners (owned and controlled by CEO Jacob D. Cohen) loaned $37,500 to the company on March 1, 2024, repaid on October 7, 2024, with no interest.
• Cohen Enterprises, Inc. (owned and controlled by CEO Jacob D. Cohen) loaned $50,000 on March 18, 2024, and $100,000 on April 1, 2024. These were formalized into a $150,000 promissory note on October 18, 2024, bearing 8% interest. This note was sold to Mill End Capital Ltd. on December 13, 2024, ceasing to be a related party note.
• The Tiger Cub Trust (controlled by CEO Jacob D. Cohen) loaned $100,000 to the company on May 2, 2025, evidenced by a Promissory Note with 18% interest. This note was amended on July 21, 2025, to be convertible into common stock at $1.785 per share and included warrants to purchase 50,000 shares.
• During the six months ended June 30, 2025, CEO Jacob Cohen used his personal credit card for $30,000 in payments to a third-party vendor for company services, recorded as accrued liabilities related parties.
• LT Global Practice Management (owned by CEO Jacob Cohen's wife) entered into a service agreement on January 28, 2025, to provide virtual professionals at rates between $1,800 to $3,500 per full-time professional.
• Amanda Hammer, COO, had her employment agreement amended on February 6, 2025, expanding her role to include Mango & Peaches Corp. and increasing her compensation to $180,000 per year plus a $15,000 cash bonus.
• CEO Jacob D. Cohen's employment agreement was amended on April 24, 2025, increasing his base yearly compensation to $420,000 (from $360,000), monthly office allowance to $10,000 (from $7,500), and monthly car allowance to $5,000 (from $2,500), and providing an additional 3,192,906 shares of Mango & Peaches common stock.
• On May 13, 2025, Mango & Peaches (a subsidiary) issued 4,892,906 shares of its common stock and 100 shares of its Series A Super Majority Voting Preferred Stock to Jacob Cohen, giving him 75.2% voting control over Mango & Peaches.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing equity issuances and conversions of preferred stock and debt into common stock. The increasing net losses and going concern warning indicate potential for further share price volatility and value erosion. The strategic review process could lead to outcomes that may or may not maximize shareholder value.
• **Employees/Management:** Management staff has increased, and CEO and COO compensation has risen, including substantial equity-based incentives. This could motivate key personnel but also contributes to increased operating expenses.
• **Customers:** The company's focus on expanding product offerings and enhancing its telemedicine platform aims to improve customer experience and product availability. However, the FDA non-approval status of compounded products and the Eli Lilly lawsuit settlement highlight potential regulatory and safety concerns that could impact customer trust.
• **Creditors:** The company's reliance on debt financing, including related-party loans, and the conversion of debt into equity, affects the risk profile for creditors. The going concern doubt suggests elevated risk for unsecured lenders.
• **Suppliers/Vendors:** The company's financial instability and need for continuous funding could pose risks to suppliers regarding timely payments, although no specific issues were detailed beyond general accounts payable.

Next Steps

• Complete Phase II clinical trials and efficacy studies for patented respiratory illness prevention technology by Q3 2025.
• Determine next steps for commercialization and monetization of respiratory illness prevention technology based on study results.
• Prepare marketing and distribution strategy for Dermytol and commence operations under the Master Distribution Agreement in Q3 2025.
• Continue to make additional and ongoing technology enhancements to the telemedicine platform.
• Further develop, market, and advertise additional men's health and wellness related products on the telemedicine platform.
• Identify strategic acquisitions that complement the company's vision in the technology, health, and wellness space.
• Seek additional funding through equity financings, debt financings, or other capital sources to support operations and growth.

Key Dates

Recommendation

Mangoceuticals presents a highly speculative investment with substantial risks. The company exhibits a deteriorating financial position, marked by significantly increasing net losses, declining year-over-year revenue, and a persistent working capital deficit. The explicit 'going concern' warning from management and auditors underscores severe liquidity issues. While strategic IP acquisitions and product diversification are underway, their commercial viability and contribution to profitability remain unproven. The heavy reliance on dilutive equity financing, including numerous common stock and warrant issuances, will continue to erode shareholder value. Furthermore, the company operates in a complex regulatory environment with non-FDA approved products, posing legal and operational risks, as evidenced by the Eli Lilly lawsuit. The high level of related-party transactions also raises corporate governance concerns. Given the fundamental financial distress, high operational burn rate, and continuous need for dilutive capital, a seasoned investor would likely recommend a strong sell, as the risks far outweigh any potential, highly uncertain, future rewards.

Keywords

telemedicine, mens wellness, pharmaceutical products, ED treatment, hair loss treatment, testosterone replacement therapy, weight management, nutraceuticals, intellectual property, SEC filing, 10-Q/A, MGRX, biotechnology, healthcare technology, corporate governance, capital raise, stock-based compensation, related party transactions